TY - JOUR T1 - Atropine, Ondansetron, and Ketorolac: Supplemental Management of Amniotic Fluid Embolism JF - Ochsner Journal JO - Ochsner J SP - 253 LP - 257 DO - 10.31486/toj.21.0107 VL - 22 IS - 3 AU - Miranda Long AU - Jane Martin AU - Joseph Biggio Y1 - 2022/09/21 UR - http://www.ochsnerjournal.org/content/22/3/253.abstract N2 - Background: Amniotic fluid embolism (AFE) is a rare cause of severe maternal morbidity and mortality. No well-studied protocols are available for management of AFE. We present a case of cardiac arrest secondary to presumed AFE and the use of atropine-ondansetron-ketorolac (AOK).Case Report: A 34-year-old gravida 4, para 2012 underwent a repeat cesarean section at 39 weeks of gestation. After delivery of the placenta, hypoxia and hypotension developed, followed by cardiac arrest. Protocols for management of maternal cardiac arrest were followed. Echocardiogram demonstrated right ventricular dilation and hypokinesis. AOK was administrated during prolonged cardiac arrest, and spontaneous circulation returned. The patient was extubated on postoperative day 3 and discharged on postoperative day 10 without neurologic deficits.Conclusion: Management of AFE should include consideration of the addition of AOK to typical guidelines. ER -